Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: Critical analysis of current evidence

European Urology

Volumn 60, Issue 3, 2011, Pages 527-535

  Martínez Salamanca, Juan I ^a   Carballido, Joaquin ^a   Eardley, Ian ^b   Giuliano, Francois ^c   Gratzke, Christian ^d   Rosen, Raymond ^e   Salonia, Andrea ^f   Stief, Christian ^d  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c University of Versailles Saint Quentin en Yvelines   (France)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e NEW ENGLAND RESEARCH INSTITUTES   (United States)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Alfuzosin; Benign prostatic hyperplasia; Bladder neck; Cavernous tissue; Erectile dysfunction; Lower urinary tract symptoms; PDE receptors; Phosphodiesterase inhibitors; Sildenafil; Tadalafil; Tamsulosin; Udenafil; UK 369003; Vardenafil

Indexed keywords

ALFUZOSIN; GISADENAFIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; UDENAFIL; VARDENAFIL;

BODY MASS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DESCRIPTIVE RESEARCH; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SEXUAL FUNCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; TREATMENT OUTCOME; URODYNAMICS; UROLOGIC DISEASES;

EID: 79960994565     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.054     Document Type: Review

References (72)

1. Köhler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55:38-48.
2. Lukacs B, Leplège A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731-40. (Pubitemid 26398693)
3. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11.
4. Nicolosi A, Moreira Jr ED, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: crossnational study of the prevalence and correlates of erectile dysfunction. Urology 2003;61:201-6. (Pubitemid 36151741)
5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49. (Pubitemid 37542920)
6. Vallancien G, Emberton M, Harving N, van Moorselaar RJ. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003;169:2257-61. (Pubitemid 36576765)
7. Boyle P, Robertson C, Mazzetta C, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int 2003;92:719-25. (Pubitemid 37475814)
8. Hansen BL. Lower urinary tract symptoms (LUTS) and sexual function in both sexes. Eur Urol 2004;46:229-34.
9. Terai A, Ichioka K, Matsui Y, Yoshimura K. Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology 2004;64:132-6. (Pubitemid 38887593)
10. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int 2009;103(Suppl 3):33-41.
11. Mondul AM, Rimm EB, Giovannucci E, Glasser DB, Platz EA. A prospective study of lower urinary tract symptoms and erectile dysfunction. J Urol 2008;179:2321-6.
12. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-45. (Pubitemid 40745354)
13. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97(Suppl 2): 23-8. (Pubitemid 43356992)
14. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006;97(Suppl 2):39-46.
15. Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 2007;26(Suppl):928-33. (Pubitemid 47548230)
16. Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29-34.
17. Aktas BK, Gokkaya CS, Bulut S, Dinek M, Ozden C, Memis A. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male 2010;14:48-52.
18. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44. (Pubitemid 32771319)
19. Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005;26:182-8. (Pubitemid 40293703)
20. Roumeguère T, Zouaoui Boudjeltia K, et al. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int 2009;104:511-7.
21. Kaminetsky J. Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 2006;22:2497-506. (Pubitemid 46048365)
22. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001;65:1-52.
23. Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003;64:533-46. (Pubitemid 37048555)
24. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-9.
25. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259-63. (Pubitemid 44721238)
26. Uckert S, Kuthe A, Jonas U, et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484-90. (Pubitemid 33065340)
27. Ückert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006;49:740-5. (Pubitemid 43374744)
28. Loughney K, Taylor J, Florio VA. 3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 2005; 17:320-5.
29. Hotston M, Shukla N, Bloor J, Persad R, Jeremy JY. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1331-2. (Pubitemid 44721256)
30. Truss MC, Uckert S, Stief CG, et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res 1996;24:123-8.
31. Truss MC, Uckert S, Stief CG, et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996;24:129-34.
32. Qiu Y, Kraft P, Craig EC, et al. Identification and functional study of phosphodiesterases in rat urinary bladder. UrolRes 2001;29:388-92. (Pubitemid 34042184)
33. Qiu Y, Kraft P, Craig EC, et al. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002;59:145-9. (Pubitemid 34059337)
34. Morley DJ, Hawley DM, Ulbright TM, et al. Distribution of phosphodiesterase I in normal human tissues. J Histochem Cytochem 1987;35:75-82. (Pubitemid 17221600)
35. Morelli A, Filippi S, Comeglio P, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7:107-20.
36. Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7:59-69.
37. Bittencourt JA, Tano T, Gajar SA, et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology 2009;73:427-30.
38. Gillespie JI, Markerink-van Ittersum M, De Vente J. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: Evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res 2006;325:325-32. (Pubitemid 44050798)
39. Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29.
40. Oger S, Behr-Roussel D, Gorny D, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 2010;160:1135-43.
41. Andersson K-E, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56:581-631. (Pubitemid 40003785)
42. Morita T, Ando M, Kihara K, et al. Effects of prostaglandins E1, E2 and F2 alpha on contractility and cAMP and cGMP contents in lower urinary tract smooth muscle. Urol Int 1994;52:200-3.
43. Werkstrom V, Alm P, Persson K, et al. Inhibitory innervation of the guinea pig urethra; roles of CO, NO and VIP. J Auton Nerv Syst 1998;74:33-42. (Pubitemid 28517855)
44. Werkstrom V, Svensson A, Andersson K-E, et al. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 2006;98:414-23.
45. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010;62:525-63.
46. Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010;11:1109-22.
47. Kuthe A, Montorsi F, Andersson K-E, et al. Phosphodiesterase inhibitors for the treatment of erectile dysfunction. Curr Opin Investig Drugs 2002;3:1489-95.
48. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7:524-40.
49. Sairam K, Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90:836-9. (Pubitemid 36693615)
50. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
51. Cockett AT, Aso Y, Denis L, et al. World Health Organization Consensus Committee recommendations concerning the diagnosis of BPH. Prog Urol 1991;1:957-72.
52. Chang HS, Park CH, Kim CI, et al. Influence of sildenafil on lower urinary tract symptoms. Eur Urol Suppl 2006;5:178.
53. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-7.
54. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, Van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia a randomized, double-blind trial. J Urol 2007;177:1071-7. (Pubitemid 46216352)
55. McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of body mass index or LUTS severity. Urology 2008;72:575-9.
56. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7. (Pubitemid 46435965)
57. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
58. Roehrborn RC. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo controlled trial. Urology 2001;58:953-9.
59. Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999;31:335-41. (Pubitemid 30041837)
60. Kraus SR, Dmochowski R, Albo ME, Xu L, Klise SR, Roehrborn CG. Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourol Urodyn 2010;29:741-7.
61. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with and without erectile dysfunction. Urology 2010;75:1452-9.
62. Kim TB, Kim KH, Yoon SJ. Open-label, intermittent dose, prospective study evaluating the effects of tadalafil on lower urinary tract symptoms and erectile function in patients with benign prostatic hyperplasia: continuation and durability of effects. Int Neurourol J 2010; 14:7-12.
63. Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2010; 183:1092-7.
64. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53: 1236-44.
65. Helmy H, Rasheed M, Al-Abd S. Vardenafil improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled trial. Eur Urol Suppl 2009;8:238.
66. Giuliano FA, Lamb J, Crossland A, et al. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment ofmenwith storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int 2010;106: 666-73.
67. Tamimi NA, Mincik I, Haughie S, et al. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010;106:674-80.
68. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51: 1717-23. Corrigendum. Eur Urol 2008;53:1320.
69. Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009;6:544-52.
70. Bechara A, Romano S, Casabe A, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-8.
71. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010;28:17-22.
72. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009;2:122-8.